{"id":"e515a0ec-efaf-5e3e-8ee0-b4fb735d3ee0","stable_key":"16c35a72-8162-5bb1-ae01-45331b8b42d0:moringa-nevirapine-pk-null","predicate":"does_not_materially_change","statement":"In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"64aa0b1b-056b-5794-bc0c-bd4e6563f9e4","mechanism_event_label":"In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.","subject":{"id":"994f4608-74f6-55d1-b36b-f9284fce9960","slug":"moringa-leaf-powder","display_name":"Moringa dry leaf powder","entity_type_key":"botanical"},"object":{"id":"3746c9ee-378a-5cf4-a355-bfd738e0a276","slug":"human-nevirapine-steady-state-exposure","display_name":"Steady-state nevirapine AUC, Cmax and 12-hour concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"64aa0b1b-056b-5794-bc0c-bd4e6563f9e4","stable_key":"16c35a72-8162-5bb1-ae01-45331b8b42d0:moringa-nevirapine-pk-null-event","event_type":"observed_relationship","label":"In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.","description":"In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"994f4608-74f6-55d1-b36b-f9284fce9960","slug":"moringa-leaf-powder","display_name":"Moringa dry leaf powder","entity_type_key":"botanical"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3746c9ee-378a-5cf4-a355-bfd738e0a276","slug":"human-nevirapine-steady-state-exposure","display_name":"Steady-state nevirapine AUC, Cmax and 12-hour concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"d3967839-e356-53f9-b59c-5933d44f1171","slug":"nevirapine","display_name":"Nevirapine","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Nevirapine alone then with 1.85 g/day Moringa leaf powder","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"14 days coadministration","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Adults with HIV receiving steady-state nevirapine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"moringa","display_name":"Moringa oleifera","entity_type_key":"botanical"}},{"dimension":"organism","value_text":"Adults with HIV receiving steady-state nevirapine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Intensive 12-hour nevirapine pharmacokinetics","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7d33be3d-d3b5-5ec5-b129-843ea945226c","evidence_kind":"source_excerpt","locator":"Lines 178-187","start_line":178,"end_line":187,"excerpt":"## moringa-nevirapine-pk-null\nIn eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.\nModel/species: Adults with HIV receiving steady-state nevirapine\nTissue/system: Intensive 12-hour nevirapine pharmacokinetics\nExposure: Nevirapine alone then with 1.85 g/day Moringa leaf powder\nRoute: Oral\nDuration: 14 days coadministration\nLimits: The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation.\nPrimary reference: Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Adults with HIV receiving steady-state nevirapine","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2752e9b3-e4b9-55fe-be07-944204cca4b8","stable_key":"import-16c35a72-8162-5bb1-ae01-45331b8b42d0","title":"Moringa oleifera: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"c4146a85ed4997fa117a83862fcf605ffb74110cf9f9cac8c63d1f6b07b8a57c","revision_id":"399ef3a4-8939-5df0-9f90-71d41dd6bab8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}